Physician profile
Jason Postula-Stein
NPI 1710915905
$6,266.40
in general payments reported to CMS, 2019-2025
45 companies · $942 in 2025
The $942 reported for 2025 was more than what 85% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $540 · 2020: $649 · 2021: $1,466 · 2022: $939 · 2023: $1,208 · 2024: $523 · 2025: $942.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,673.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,673.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $988.31 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Abbvie INC. | $843.77 | 2019-2025 | |
| Lilly USA, LLC | $574.53 | 2019-2025 | Mounjaro, Zepbound, Emgality |
| Glaxosmithkline, LLC. | $524.13 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Pfizer INC. | $500.87 | 2019-2025 | |
| Novo Nordisk INC | $492.05 | 2019-2025 | Ozempic, Wegovy, Rybelsus |
| Exact Sciences Corporation | $251.74 | 2023-2025 | Cologuard Collection Kit |
| Bayer Healthcare Pharmaceuticals INC. | $152.97 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $151.72 | 2019-2022 | |
| Amgen INC. | $150.46 | 2020-2024 | Otezla, Repatha, Prolia |
| Biohaven Pharmaceutical Holding Company LTD. | $146.28 | 2022 | |
| Amarin Pharma, INC. | $145.83 | 2020-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $126.15 | 2020-2023 | Ofev |
| Teva Pharmaceuticals USA, INC. | $113.11 | 2019-2022 | |
| Idorsia Pharmaceuticals US INC | $83.17 | 2022-2023 | Quviviq |
Show all 45 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jason Postula-Stein listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.